摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-fluoro-N-((6-(di flu oromethyl)-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)-2,2-dimethylpropanamide

中文名称
——
中文别名
——
英文名称
3-fluoro-N-((6-(di flu oromethyl)-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)-2,2-dimethylpropanamide
英文别名
N-[[6-(difluoromethyl)-5-[5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl]pyridin-3-yl]methyl]-3-fluoro-2,2-dimethylpropanamide
3-fluoro-N-((6-(di flu oromethyl)-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)-2,2-dimethylpropanamide化学式
CAS
——
化学式
C21H19F6N5O2
mdl
——
分子量
487.4
InChiKey
WZSUFMMZCBDIKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    34
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    86.7
  • 氢给体数:
    2
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLONE UTILISÉS COMME INHIBITEURS DE LA MPGES-1
    申请人:GLENMARK PHARMACEUTICALS SA
    公开号:WO2013186692A1
    公开(公告)日:2013-12-19
    The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    本公开涉及式(I)的化合物及其药用盐,作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1(mPGES-1)酶的抑制剂,因此在治疗来自各种疾病或病况的疼痛和/或炎症方面具有用处,如哮喘、骨关节炎、类风湿关节炎、急性或慢性疼痛和神经退行性疾病。
  • Triazolone compounds as MPGES-1 inhibitors
    申请人:Glenmark Pharmaceuticals S.A.
    公开号:US10391083B2
    公开(公告)日:2019-08-27
    The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    本公开涉及作为 mPGES-1 抑制剂的式 (I) 化合物及其药学上可接受的盐。这些化合物是微粒体前列腺素 E 合酶-1(mPGES-1)酶的抑制剂,因此可用于治疗多种疾病或病症引起的疼痛和/或炎症,如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。
  • TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS
    申请人:Glenmark Pharmaceuticals S.A.
    公开号:US20180200229A1
    公开(公告)日:2018-07-19
    The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
  • US9096545B2
    申请人:——
    公开号:US9096545B2
    公开(公告)日:2015-08-04
  • US9439890B2
    申请人:——
    公开号:US9439890B2
    公开(公告)日:2016-09-13
查看更多